
Experience
ACELYRIN Announces Pricing of Upsized Initial Public Offering
May 15, 2023
Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.
Related contacts
SCYNEXIS Announces Exclusive License Agreement With GSK for Brexafemme
April 4, 2023
Cooley advised SCYNEXIS on its exclusive license agreement with GSK for Brexafemme.
Related contacts
Structure Therapeutics – $185.3 Million IPO
February 9, 2023
San Francisco – February 9, 2023 – Cooley advised Structure Therapeutics, a clinical-stage global biopharmaceutical company, on its $185.3 million initial public offering, including the full exercise of the underwriters’ option to purchase additional American depositary shares. Lawyers Charlie Kim, Patrick Loofbourrow, Andrew Harline and Su Lian Lu led the Cooley team.
The offering marks the first sizable US life sciences IPO this year. Structure Therapeutics will use the proceeds to develop new oral therapies for the treatment of various diseases, including those impacting the metabolic, cardiovascular and pulmonary systems. Its lead product candidate targets Type 2 diabetes and obesity.
Structure Therapeutics aims to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages structure-based drug discovery and computational chemistry expertise, enabling it to build a pipeline of product candidates. The company currently focuses on G-protein-coupled receptors as a therapeutic target class.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
Related contacts
CinCor Pharma to Sell to AstraZeneca for Approximately $1.8 Billion
January 10, 2023
Cooley advised CinCor Pharma, a clinical-stage biopharmaceutical company, on its definitive agreement to be acquired by AstraZeneca. M&A partners Rama Padmanabhan and Rowook Park and corporate partners Div Gupta and Sarah Sellers led the Cooley team.
Related contacts
Tmunity Therapeutics Agrees to Sell to Kite
December 28, 2022
Cooley advised Tmunity Therapeutics, a clinical-stage biotechnology company, on its agreement to sell to Kite, a global biopharmaceutical company. Partners Mark Weeks, Ben Beerle and Marya Postner led the Cooley team.
Related contacts
Related news and events
Memberships & affiliations
American Bar Association
American Health Lawyers Association